azd-8055
Small moleculeexperimental
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2008 (NCT00731263)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Serine/threonine-protein kinase mTORINHIBITOR
MTOR inhibitor
ATP-competitive mTORC1/mTORC2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO- Mol. weight
- 465.55 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1801204 ↗
Also known as
- (5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol
- az-12600000
- az-12600000
- azd8055
- azd8055
- azd8055
- azd-8055
- azd-8055
- azd-8055
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01316809 | Phase 1 | Mar 4, 2011 | National Cancer Institute (NCI) |
| NCT01194193 | Phase 1 | Aug 18, 2010 | AstraZeneca |
| NCT00999882 | Phase 1 | Oct 1, 2009 | AstraZeneca, City University of Hong Kong |
| NCT00973076 | Phase 1 | Aug 1, 2009 | AstraZeneca |
| NCT00731263 | Phase 1 | Jul 1, 2008 | AstraZeneca, Cornell University, Royal Marsden Hospital NHS Trust, University of Texas at Houston |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 4 | 4 | 1 | 2008 |
| City University of Hong Kong | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2008 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2011 |
| Royal Marsden Hospital NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2008 |
6 organizations
Page 1 / 1